MicroRNA-133a Inhibits Proliferation of Gastric Cancer Cells by Downregulating ERBB2 Expression
Related Experiment Video
Updated: Feb 9, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Abstract:
Gastric cancer is the fourth most common type of cancer and the second highest leading cause of cancer-related deaths worldwide. It has already been established that miR-133a is involved in gastric cancer. In this study, we investigated the molecular mechanisms by which miR-133a inhibits the proliferation of gastric cancer cells. We analyzed the proliferative capacity of human gastric cancer cells SNU-1 using an MTT assay. Cell apoptosis was determined using flow cytometry. The expression levels of ERBB2, p-ERK1/2, and p-AKT in SNU-1 cells were determined using Western blot analysis. To confirm that ERBB2 is a direct target of miR-133a, a luciferase reporter assay was performed. Results showed that miR-133a overexpression inhibited SNU-1 cell proliferation and increased apoptosis. ERBB2 was a direct target of miR-133a, and it was negatively regulated by miR-133a. Interestingly, ERBB2 silencing has a similar impact to miR-133a overexpression, in that it significantly induced apoptosis and inhibited ERK and AKT activation. Our study showed that miR-133a inhibits the proliferation of gastric cancer cells by downregulating the expression of ERBB2 and its downstream signaling molecules p-ERK1/2 and p-AKT. Therefore, miR-133a might be used as a therapeutic target for treating gastric cancer.
Insights
MicroRNA-133a (miR-133a) inhibits gastric cancer cell growth by targeting ERBB2. This finding suggests miR-133a as a potential therapeutic target for gastric cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Gastric cancer is a leading cause of cancer deaths globally.
- MicroRNA-133a (miR-133a) has been implicated in gastric cancer development.
- The precise molecular mechanisms of miR-133a's role in gastric cancer require further elucidation.
Purpose of the Study:
- To investigate the molecular mechanisms underlying miR-133a's inhibition of gastric cancer cell proliferation.
- To identify direct molecular targets of miR-133a in gastric cancer cells.
- To explore the potential of miR-133a as a therapeutic agent for gastric cancer.
Main Methods:
- MTT assay to analyze cell proliferation in SNU-1 gastric cancer cells.
- Flow cytometry to assess apoptosis.
- Western blot analysis to measure protein expression levels of ERBB2, p-ERK1/2, and p-AKT.
- Luciferase reporter assay to confirm ERBB2 as a direct target of miR-133a.
Main Results:
- Overexpression of miR-133a significantly inhibited SNU-1 cell proliferation and induced apoptosis.
- ERBB2 was identified as a direct target of miR-133a, with its expression being negatively regulated.
- Silencing ERBB2 mimicked the effects of miR-133a overexpression, inducing apoptosis and inhibiting ERK and AKT activation.
Conclusions:
- miR-133a suppresses gastric cancer cell proliferation by downregulating ERBB2 expression and its downstream signaling pathways (p-ERK1/2, p-AKT).
- ERBB2 acts as a direct molecular target mediating the tumor-suppressive effects of miR-133a.
- miR-133a presents a promising therapeutic target for gastric cancer treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Feedback Inhibition
Cells Coordinate Growth and Proliferation
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...

